Ghrelin Tedavisi Overleri Cerrahi Olarak Çıkarılmış Sıçanlarda Lipit Metabolizmasını ve Hepatik Dejenerasyonu Düzeltir

  • Esra Bihter Gürler
  • Dilek Özbeyli
  • Özlem Tuğçe Çilingir Kaya
  • Feriha Ercan
  • Berrak Ç. Yeğen

Abstract

Amaç: Menopoz sonrası dönemde ortaya çıkan metabolik bozukluklar kadınlarda yağlı karaciğer hastalığı gelişme riskini arttırmaktadır. Bu çalışmanın amacı, ghrelinin overektomize (OVT) sıçanlarda metabolik biyobelirteçler ve hepatik morfoloji üzerindeki etkilerini değerlendirmektir. Gereç Ve Yöntem: Ketamin-klorpromazin anestezisi altında (100 mg / kg, 0,75 mg / kg), Sprague-Dawley sıçanlarına (n = 12) çift taraflı OVT, kontrol grubunda taklit cerrahi uygulandı (n = 6). Ameliyattan dört hafta sonra, OVT sıçanlarının yarısı 4 hafta boyunca oral olarak ghrelin (1 mg / kg / hafta) ile tedavi edildi, diğerleri tedavi edilmedi. 8. hafta sonunda kardiyak ponksiyon ile ötenazi yapılarak serum glukoz, insülin, aspartat aminotransferaz (AST), yüksek yoğunluklu lipoprotein (HDL), düşük yoğunluklu lipoprotein (LDL), çok düşük yoğunluklu lipoprotein (VLDL), trigliseritler, östradiol ve progesteron, otomatik bir analizör ile ölçülmüştür. Bulgular: 2 ay sonunda OVT ile artan (p <0,001) vücut ağırlıkları, ghrelin ile değişmedi. Serum östradiol ve progesteron seviyeleri değişmiş gonadal hormon durumu doğrulayacak şekilde azaldı (p <0,05), ancak insülin ve glukoz düzeyleri değişmedi. Düşmüş HDL ve artmış LDL düzeyleri (p <0,05), tedavi edilmemiş OVT sıçanlarında belirgindi, ghrelin tedavisi LDL düzeylerini düşürdü (p <0,05), ancak HDL seviyelerini değiştirmedi. Bununla birlikte, OVT sıçanlarında ghrelin, trigliseritleri, VLDL ve AST seviyelerini anlamlı düzeyde düşürdü (p <0,05). OVT grubunda ortaya çıkan sinüzoidal konjesyon, aktifleşmiş Kupffer hücreleri ve balonlaşma şeklinde hasarlanmış hepatositlerde ghrelin tedavisi ile düzelme görüldü. Sonuç: Sonuç olarak menopoz sonrası erken dönemde hafif dislipidemi ve hepatik dejenerasyonun ghrelin tedavisi ile azaldığı ve çalışmanın daha fazla araştırma gerektirdiği görülmektedir.

References

Garg SK, Maurer H, Reed K, Selagamsetty R. Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes Obes Metab. 2013;16(2):97-110)

Chen KL, Madak-Erdogan Z. Estrogens and female liver health. Steroids. 2017; Nov1. pii: S0039-128X(17)301

Morling JR, Balkau B, Wild SH. Diabetes in women: a lifecourseapproach. Menopause Int 2013;19:87–95.

Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008;28:339–50.

Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. Prevalence of primary nonalcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int 2006;26:856–63.

Park SH, Jeon WK, Kim SH, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 2006;21:138–43.

Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960–7.

. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006;40:S5-10.

Suzuki A, Abdelmalek MF. Nonalcoholic fatty liver disease in women. Womens Health 2009;5:191-203.

Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR. Increased visceral fat and decreased energy expenditure during the menopausal transition,. International Journal of Obesity 2008; 32:6: 949–958.

Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656—60.

Tschop M, Smiley DL, Heiman ML.Ghrelin induces adiposity in rodents Nature 2000;407: 908-913.

Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K et al.A role for ghrelin in the central regulation of feding Nature 2001, 409:194-198

Hewson AK, Dickson SL. Systemic administration of ghrelin induces Fos and Egr-1 proteins in the hypothalamic arcuate nucleus of fasted and fed rats J Neuroendocrinol 2000; 12: 1047-1049.

Goldstone AP. Prader-Willi syndrome: advances in genetics, pathophysiology and treatment, Trends Endocrinol Metab 2004; 15:12-20.

Davies JS, Kotokorpi P, Eccles SR et al. Ghrelin induces abdominal obesity via GHS-R-dependent lipid retention. Molecular endocrinology. 2009;23:914–924.

Sato T, Ida T, Nakamura Y et al. Physiological roles of ghrelin on obesity,Obesity Research & Clinical Practice 2014; 8(5):e405-e413.

Lin L, Saha PK, Ma X et al.Ablation of ghrelin receptor reduces adiposity and improves insulin sensitivity during aging by regulating fat metabolism in white and brown adipose tissues. Aging cell. 2011;10:996–1010.

Zigman JM, Bouret SG, Andrews ZB. Correction to 'Obesity Impairs the Action of the Neuroendocrine Ghrelin System. Trends in Endocrinology and Metabolism 2016;27(348):54-63.

Briggs DI, Enriori PJ, Lemus MB, Cowley MA, Andrews ZB. Diet-induced obesity causes ghrelin resistance in arcuate NPY/AgRP neurons. Endocrinology 2010; 151:4745- 4755.

Briggs DI, Lemus MB, Kua E, Andrews ZB. Diet-induced obesity attenuates fastinginduced hyperphagia. J Neuroendocrinol 2011; 23:620-626.

Gnanapavan S, Kola B, Bustin SA, Morris DG et al.The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002; 87:2988

Dixit VD, Schaffer EM, Pyle RS et al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 2004; 114:57-66.

Estep M, Abawi M, Jarrar M et al. Association of obestatin, ghrelin, and inflammatory cytokines in obese patients with non-alcoholic fatty liver disease. Obes Surg, 2011; 21:1750-1757.

Cheng J, Zhang L, Dai W et al. Ghrelin ameliorates intestinal barrier dysfunction in experimental colitis by inhibiting the activation of nuclear factor-kappa B,Biochemical and Biophysical Research Communications 2015;458(1):140-147.

Corriveau P, Paquette A, Brochu M, Prud'homme D, Rabasa-Lhoret R, Lavoie JM. Resistance training prevents liver fat accumulation in ovariectomized rats. Maturitas 2008;59:259-67.

Gutierrez-Grobe Y, Ponciano-Rodríguez G, Ramos MH, Uribe M, Méndez-Sánchez N. Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol. 2010 Oct-Dec;9(4):402-9.

Ahmed MH, Abu EO, Byrne CD. Non-Alcoholic Fatty Liver Disease (NAFLD): new challenge for general practitioners and important burden for health authorities? Prim Care Diabetes. 2010;4:129–137

Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.N Engl J Med. 2010 Sep 30; 363(14):1341-50.

Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterology 2014;5:211-218.

Norris AL, Steinberger J, Steffen LM, Metzig AM, Schwarzenberg SJ, Kelly AS. Circulating oxidized LDL and inflammation in extreme pediatric obesity.Obesity (Silver Spring). 2011 Jul; 19(7):1415-9.

Zhang QQ, Lu LG. Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy. J Clin Transl Hepatol. 2015;3(1):78-84.

Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.Gastroenterology. 1999 Jun; 116(6):1413-9.

Wassmann S, Baumer AT, Strehlow K et al., Endothelial Dysfunction and Oxidative Stress During Estrogen Deficiency in Spontaneously Hypertensive Rats. Circulation 2001; 103(3), 435–441.

Fabricio V, Oishi JC, Biffe BG, et al. Resveratrol Treatment Normalizes the Endothelial Function and Blood Pressure in Ovariectomized Rats. Arq Bras Cardiol. 2017;108(2):116-121.

Mao Y, Tokudome T; Kishimoto K. Ghrelin As a Treatment for Cardiovascular Diseases. Hypertension 2014; 64(3):450–454.

Lilleness BM; Frishman WH. Ghrelin and the Cardiovascular System. Cardiology in Review 2016 24(6):288–297.

Zhang QQ, Lu LG. Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy. J Clin Transl Hepatol. 2015;3(1):78-84.

nmic.ie [homepage on the Internet]. Dublin: National Medicines Information Center NMIC Bulletins 2006 12:4 [updated 16 November 2018; cited 5 January 2019]. Available from: www.stjames.ie/GPsHealthcareProfessionals/Newsletters/NMICBulletins/NMICBulletins2006/Update%20on%20Lipid-Lowering%20Therapies%20Vol.12%20No.4%202006.pdf.

Rao MS, Subbarao V, Reddy JK. Peroxisome proliferator-induced hepatocarcinogenesis: histochemical analysis of ciprofibrate-induced preneoplastic and neoplastic lesions for gamma-glutamyl transpeptidase activity. J Natl Cancer Inst. 1986;77:951–956.

Yu S, Rao S, Reddy JK. Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. Curr Mol Med. 2003;3:561–572.

Gonzalez FJ, Peters JM, Cattley RC. Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha. J Natl Cancer Inst. 1998;90:1702–1709.

Sehirli O, Sener E, Sener G, Cetinel S, Erzik C, Yeğen BC.Ghrelin improves burn-induced multiple organ injury by depressing neutrophil infiltration and the release of pro-inflammatory cytokines. Peptides 2008; Jul;29(7):1231-40.

Işeri SO, Sener G, Saglam B, Ercan F, Gedik N, Yeğen BC.Ghrelin alleviates biliary obstruction-induced chronic hepatic injury in rats.Regul Pept 2008; Feb 7;146(1-3):73-9.

Kasımay O, Işeri SO, Barlas A, Bangir D, Yeğen C, Arbak S, Yeğen BC.Ghrelin ameliorates pancreaticobiliary inflammation and associated remote organ injury in rats.Hepatol Res. 2006;36(1):11-9.

Liu H, Lu HY. Nonalcoholic fatty liver disease and cardiovascular disease. World J Gastroenterol 2014; Jul 14; 20(26):8407-15.

Lippl F, et al. Low-dose ghrelin infusion—evidence against a hormonal role in food intake. Regul Pept 2012;174(1-3):26–31.

Published
2019-12-21
Section
Original Research